Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammation, Sickle Cell Disease, and Metastasis Inhibition Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for E-selectin drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SELE ECD-Fc Fusion Protein Extracellular domain (Ser28-Phe556), HEK293 expressed, Human IgG1 Fc tag. High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Native C-type lectin folding. |
View SELE Products |
| Ortholog Panel | Mouse SELE / Cyno SELE ECD-Fc Cross-species reactivity testing for preclinical translation. Sequence Verified. |
View SELE Products |
| Gene Delivery | SELE Lentivirus Premade Particles Full-length human SELE ORF for stable cell line construction. Suitable for shear-flow adhesion assays. |
View SELE Products |
| Benchmark Ab | Anti-SELE Neutralizing Antibody (Research Grade) Recombinant positive control for blocking sialyl-Lewis X binding. |
View SELE Products |
| Validator | SELE siRNA Set (3 unique sequences) For knockdown verification and specificity controls in cell-based assays. |
View SELE Products |
| Related Target: P-selectin | SELP (CD62P) Paralog selectin for selectivity screening (pan-selectin vs. specific inhibition strategies). |
View SELP Products |
| Related Target: PSGL-1 | SELPLG (P-selectin Glycoprotein Ligand-1) Primary counter-receptor for SELE; soluble recombinant protein for competitive binding assays. |
View SELPLG Products |
| Related Target: L-selectin | SELL (CD62L) Leukocyte-specific selectin for subfamily off-target liability assessment. |
View SELL Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pan-Selectin Selectivity Screening | Human/Mouse/Cyno orthologs available for SELE, SELP, and SELL with >95% purity; strict mass spec verification for glycosylation pattern consistency |
| Cross-Species Evaluation | Human, Cynomolgus, and Mouse E-selectin ortholog proteins with >95% purity and verified theoretical MW |
| Shear-Dependent Binding Validation & Endothelial Model | Lentivirus for stable SELE-expressing cell lines (CHO/HEK293); preserves native conformation for flow chamber and rolling assays under physiological shear stress; validated siRNA sets enable specificity verification |
| Glycan Binding & Ligand Competition | HEK293 expression ensures native mammalian glycosylation; high-purity ECD-Fc compatible with sialyl-Lewis X tetrasaccharide binding; low endotoxin (<1EU/µg) prevents non-specific activation |
| Positive Controls & Specificity | Clinical Benchmark Antibodies (sequence-verified biosimilar controls) and SELE siRNA Set (3 unique sequences) for knockdown verification and blocking assay standardization |
Live SELE R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for E-selectin therapeutics is intensifying, with major players shifting focus from pan-selectin small molecules to highly specific biologics targeting the C-type lectin domain (CRD). First-generation small molecule antagonists face bioavailability challenges, prompting R&D shifts toward antibody-mediated blockade for sickle cell disease vaso-occlusion and cancer metastasis prevention. Emerging strategies include glycomimetic antagonists (e.g., Uproleselan for AML), ADCs targeting SELE-expressing endothelial cells in inflamed tissues, and bispecifics simultaneously blocking SELE and ICAM-1 to prevent leukocyte extravasation. Additionally, chronic inflammatory diseases and oncology metastasis prevention are driving development of sub-Q delivery formats and high-concentration antibody formulations.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Glycomimetic Small Molecule | GlycoMimetics (e.g., Uproleselan/GMI-1271) | AML (Bone Marrow Niche Disruption), Sickle Cell Disease (SCD) | Selectivity Assay: precisely glycosylated ECD-Fc vs P/L-selectin proteins |
| Monoclonal Antibody (mAb) | Pfizer, Novartis, academic consortia | Vaso-occlusive Crisis (VOC), Inflammation | Epitope Mapping & Affinity Profiling: high-purity ECD domains and orthologs |
| Pan-Selectin Inhibitor | Small molecule developers | Vaso-occlusive crisis | Selectivity panels: SELP, SELL, SELE ortholog proteins |
| ADC | Emerging biotech | Inflammatory vasculitis | Internalization assays: high-purity ECD-Fc for binding kinetics; lentivirus for internalization in intact cells |
| Bispecific (SELE/ICAM-1) | Immunology focused biotechs | Autoimmune diseases, Metastatic Cancer | Heterodimer validation: cross-reactive Abs and dual antigen panels; lentivirus-driven stable cell lines |